8158 — China Regenerative Medicine International Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Market Cap
HK$121.70m
Enterprise Value
HK$152.69m
Revenue
HK$90.62m

Annual income statement for China Regenerative Medicine International, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.

	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	HKAS	HKAS	HKAS	HKAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	182	283	232	69.5	90.6
Cost of Revenue
Gross Profit	41.8	67.7	37.6	19.4	57.7
Selling / General / Administrative Expenses
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	209	259	223	176	71.7
Operating Profit	-26.5	23.7	9.05	-107	18.9
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-142	64.3	8.27	-108	17.8
Provision for Income Taxes
Net Income After Taxes	-154	51.8	4.55	-108	17.8
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-404	13.3	4.55	-108	17.8
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-404	13.3	4.55	-108	17.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.764	0.168	0.014	-0.376	0.058